SUBSCRIBE

Australia approves etanercept and insulin aspart biosimilars

 Posted 04/12/2020

Australia’s drug regulator announced in October 2020 the approval of etanercept and insulin aspart biosimilars.

more
FDA issues Q & A on biosimilars Guidelines | Posted 04/12/2020
Cost savings after switching to generic tacrolimus Generics/Research | Posted 04/12/2020
Real-world data on biosimilars in inflammatory... Biosimilars/Research | Posted 04/12/2020
Genentech sues Centus over Avastin biosimilar Biosimilars/General | Posted 04/12/2020
Study reveals wide variation in US state drug p... Biosimilars/Research | Posted 04/12/2020
22119008_l
FDA accepts application for ranibizumab biosimilar Biosimilars/News | Posted 27/11/2020
Asia Pacific countries: future demand for biosi... Biosimilars/Research | Posted 27/11/2020
The US biosimilars market in 2020 Reports | Posted 27/11/2020
19646665_l
Biosimilar toolkit for cancer patients Biosimilars/General | Posted 27/11/2020
Biopharmaceuticals and biosimilars: regulatory... Biosimilars/Research | Posted 27/11/2020
Equivalent adherence with brand and generic ost... Generics/Research | Posted 27/11/2020
FDA new and revised guidances for complex gener... Guidelines | Posted 27/11/2020
Pfizer sues Aurobindo and Dr Reddy’s over Ibran... Generics/General | Posted 27/11/2020
Canada approves enoxaparin biosimilars Inclunox... Biosimilars/News | Posted 20/11/2020
Discontinuation following biosimilar switching... Biosimilars/Research | Posted 20/11/2020
Biosimilars trend report 2020 Reports | Posted 20/11/2020
Switching V19A17
Alberta Biosimilars Initiative: switching polic... Biosimilars/General | Posted 20/11/2020
Global harmonization of GMP standards for biolo... Biosimilars/Research | Posted 20/11/2020
Biden vows to protect Obamacare and increase re... Policies & Legislation | Posted 20/11/2020
China prioritizes drug innovation while increas... Generics/General | Posted 20/11/2020
Teva launches first Truvada and Atripla generic... Generics/News | Posted 20/11/2020
A blueprint for biosimilar assessment without e... Biosimilars/Research | Posted 13/11/2020
Pharmacokinetics and generic drug switching: a... Generics/Research | Posted 13/11/2020
Biosimilar advances for Celltrion Healthcare Biosimilars/General | Posted 13/11/2020
AffaMed and EverInsight merger announced Pharma News | Posted 13/11/2020
EMA recommends approval of Lenalidomide Mylan Generics/News | Posted 13/11/2020
Copy biological approvals in China, compared to... Biosimilars/Research | Posted 13/11/2020
GBMA publishes information resources on biosimi... Biosimilars/General | Posted 13/11/2020
COVID-19 vaccine progress and FDA approvals for... Generics/News | Posted 13/11/2020
19646665_l
Rationale for biosimilar assessment without eff... Biosimilars/Research | Posted 06/11/2020
Innovent and Eli Lilly receive approval for rit... Biosimilars/News | Posted 06/11/2020
UK releases post-Brexit biosimilar guidelines Guidelines | Posted 06/11/2020
Shared decision-making and the transition to bi... Biosimilars/Research | Posted 06/11/2020
Brazil sees a COVID vaccine setback but treatme... Generics/General | Posted 06/11/2020
Essex and Henlius collaborate to deliver bevaci... Pharma News | Posted 06/11/2020
Smart healthcare spending and the Falsified Med... Reports | Posted 06/11/2020
Changes to New Zealand law for quick access to... Policies & Legislation | Posted 06/11/2020
International Psoriasis Council releases consen... Biosimilars/General | Posted 30/10/2020
Canada approves trastuzumab biosimilar Kanjinti Biosimilars/News | Posted 30/10/2020
Role of efficacy trials in biosimilar assessmen... Biosimilars/Research | Posted 30/10/2020
Challenges faced by biosimilar orphan drugs in... Reports | Posted 30/10/2020
Perceptions of biosimilars and switching in Ara... Biosimilars/Research | Posted 30/10/2020
AbbVie accused of anticompetitive tactics to st... Policies & Legislation | Posted 30/10/2020
Medicure and Reliance sign cardiovascular drug... Pharma News | Posted 30/10/2020
FDA approves Glenmark and Cipla generics Generics/News | Posted 30/10/2020
EMA accepts application for ranibizumab biosimi... Biosimilars/News | Posted 23/10/2020
Biosimilar assessments: do we need efficacy tri... Biosimilars/Research | Posted 23/10/2020
Commercialization challenges for biosimilar orp... Reports | Posted 23/10/2020
Biopharmaceuticals and biosimilars: manufacturi... Biosimilars/Research | Posted 23/10/2020
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 05/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Country Focus

All countries

Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!

Generics News Research General

more

Biosimilars News Research General

more

More editorial sections